BioSpace News Archive

Despite the poor Q1 economic data that is beginning to be released, the equity markets are stabilizing.

A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.

The Regenstrief Institute and Indiana University are launching a survey to conduct research about COVID-19 symptoms.

Need for smarter and smaller sensors will dominate the global body sensor market between 2017 and 2022.

According to a new TMR report, the benign prostatic hyperplasia treatment market is expected to grow at a robust 6% CAGR during 2019 to 2027.

Medicinal services related contaminations or careful site diseases are the diseases procured among patients amid their emergency clinic remain, making requirements for careful disease control.

Mind Medicine Inc., the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market.

Motus Nova was recognized by the Emory Entrepreneurship Network for leading innovation in technology with its robotic at-home stroke rehab devices

OliX Pharmaceuticals , Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced the appointment of Dr. Gordon Jiang, Dr. Aaron Hakim and Dr. Yury V. Popov to its Scientific Advisory Board (SAB). The SAB will work with OliX Pharmaceuticals executive team to refine the emerging pipeline as well as clinical strategy for the company’s assets. “We are pleased to welcome Dr. Jiang, Dr. Hakim and Dr.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States Food and Drug Administration (“FDA”) denied the Citizen Petition filed by Clarus Therapeutics Inc. (“Clarus”) on October 2 , 2019. Specifically, the FDA declined to issue